PT3127544T - Fármaco antitumoral que contém complexo de platina antitumoral e potenciador de efeito antitumoral - Google Patents
Fármaco antitumoral que contém complexo de platina antitumoral e potenciador de efeito antitumoralInfo
- Publication number
- PT3127544T PT3127544T PT157739632T PT15773963T PT3127544T PT 3127544 T PT3127544 T PT 3127544T PT 157739632 T PT157739632 T PT 157739632T PT 15773963 T PT15773963 T PT 15773963T PT 3127544 T PT3127544 T PT 3127544T
- Authority
- PT
- Portugal
- Prior art keywords
- tumor
- platinum complex
- drug containing
- effect enhancer
- tumor effect
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title 2
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- 239000003623 enhancer Substances 0.000 title 1
- 229910052697 platinum Inorganic materials 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014078242 | 2014-04-04 | ||
| JP2015024802 | 2015-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3127544T true PT3127544T (pt) | 2021-11-08 |
Family
ID=54240714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT157739632T PT3127544T (pt) | 2014-04-04 | 2015-04-03 | Fármaco antitumoral que contém complexo de platina antitumoral e potenciador de efeito antitumoral |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10092589B2 (pt) |
| EP (1) | EP3127544B1 (pt) |
| JP (1) | JP6458007B2 (pt) |
| KR (1) | KR101964169B1 (pt) |
| AU (1) | AU2015242786B2 (pt) |
| CY (1) | CY1124709T1 (pt) |
| DK (1) | DK3127544T3 (pt) |
| ES (1) | ES2896051T3 (pt) |
| HR (1) | HRP20211709T8 (pt) |
| HU (1) | HUE056497T2 (pt) |
| LT (1) | LT3127544T (pt) |
| NZ (1) | NZ725067A (pt) |
| PL (1) | PL3127544T3 (pt) |
| PT (1) | PT3127544T (pt) |
| RS (1) | RS62560B1 (pt) |
| RU (1) | RU2678103C2 (pt) |
| SI (1) | SI3127544T1 (pt) |
| UA (1) | UA121862C2 (pt) |
| WO (1) | WO2015152407A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49882A (fr) * | 2017-03-17 | 2020-06-24 | Servier Lab | Combinaison entre trifluridine/ chlorhydrate de tipiracil, complexe de platine anti-tumoral et modulateur de point de contrôle immunitaire |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2191340C (en) | 1995-03-29 | 2001-04-17 | Shingo Yano | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
| CZ288406B6 (en) * | 1998-05-27 | 2001-06-13 | Lachema Np | Platinum complex of oxidation number II, process for preparing such complex, the complex functioning as medicament and pharmaceutical composition in which the complex is comprised |
| US7799783B2 (en) * | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP5681108B2 (ja) * | 2008-08-04 | 2015-03-04 | ワイス・エルエルシー | ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ |
| AU2010252280A1 (en) * | 2009-05-25 | 2012-01-19 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| WO2012012404A1 (en) * | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| US20140286902A1 (en) * | 2011-11-02 | 2014-09-25 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
-
2015
- 2015-04-03 PT PT157739632T patent/PT3127544T/pt unknown
- 2015-04-03 HU HUE15773963A patent/HUE056497T2/hu unknown
- 2015-04-03 NZ NZ725067A patent/NZ725067A/en unknown
- 2015-04-03 LT LTEPPCT/JP2015/060635T patent/LT3127544T/lt unknown
- 2015-04-03 KR KR1020167030250A patent/KR101964169B1/ko active IP Right Grant
- 2015-04-03 AU AU2015242786A patent/AU2015242786B2/en active Active
- 2015-04-03 PL PL15773963T patent/PL3127544T3/pl unknown
- 2015-04-03 US US15/301,807 patent/US10092589B2/en active Active
- 2015-04-03 RU RU2016143220A patent/RU2678103C2/ru active
- 2015-04-03 UA UAA201611039A patent/UA121862C2/uk unknown
- 2015-04-03 RS RS20211361A patent/RS62560B1/sr unknown
- 2015-04-03 EP EP15773963.2A patent/EP3127544B1/en active Active
- 2015-04-03 DK DK15773963.2T patent/DK3127544T3/da active
- 2015-04-03 SI SI201531739T patent/SI3127544T1/sl unknown
- 2015-04-03 JP JP2016511647A patent/JP6458007B2/ja active Active
- 2015-04-03 HR HRP20211709TT patent/HRP20211709T8/hr unknown
- 2015-04-03 ES ES15773963T patent/ES2896051T3/es active Active
- 2015-04-03 WO PCT/JP2015/060635 patent/WO2015152407A1/ja active Application Filing
-
2021
- 2021-11-09 CY CY20211100965T patent/CY1124709T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS62560B1 (sr) | 2021-12-31 |
| JP6458007B2 (ja) | 2019-01-23 |
| LT3127544T (lt) | 2021-11-25 |
| NZ725067A (en) | 2019-01-25 |
| EP3127544A4 (en) | 2017-12-13 |
| DK3127544T3 (da) | 2021-11-08 |
| UA121862C2 (uk) | 2020-08-10 |
| JPWO2015152407A1 (ja) | 2017-04-13 |
| CY1124709T1 (el) | 2022-07-22 |
| AU2015242786B2 (en) | 2018-11-22 |
| KR101964169B1 (ko) | 2019-04-01 |
| HUE056497T2 (hu) | 2022-02-28 |
| SI3127544T1 (sl) | 2021-12-31 |
| EP3127544B1 (en) | 2021-09-15 |
| EP3127544A1 (en) | 2017-02-08 |
| HRP20211709T8 (hr) | 2022-03-04 |
| AU2015242786A1 (en) | 2016-11-10 |
| US10092589B2 (en) | 2018-10-09 |
| HRP20211709T1 (hr) | 2022-02-04 |
| WO2015152407A1 (ja) | 2015-10-08 |
| KR20160140839A (ko) | 2016-12-07 |
| PL3127544T3 (pl) | 2022-01-03 |
| RU2016143220A3 (pt) | 2018-08-24 |
| RU2016143220A (ru) | 2018-05-07 |
| ES2896051T3 (es) | 2022-02-23 |
| US20170216339A1 (en) | 2017-08-03 |
| RU2678103C2 (ru) | 2019-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254714B (en) | History of quinoline and pharmaceutical preparations containing them | |
| HK1232224A1 (zh) | 取代脲衍生物及其在藥物中的應用 | |
| HK1244000B (zh) | 多環氨基甲酰吡啶酮化合物及其藥物用途 | |
| IL248744A0 (en) | History of heterocyclic butanamides, their preparation and drugs containing them | |
| PL3137473T3 (pl) | Pochodne Pt (iv) i zawierające je nanonośniki | |
| GB201408673D0 (en) | Medicaments,uses and methods | |
| EP3150212A4 (en) | Pharmaceutical solution having anti-tumor effect-enhancing and toxicity-reducing effect, and pharmaceutical composition comprising same | |
| IL249308B (en) | The history of quinoline, their preparation and pharmaceutical preparations containing them | |
| ZA201703398B (en) | Pharmaceutical composition and methods | |
| DK3157506T3 (da) | Smagsmaskeret oral, farmaceutisk sammensætning | |
| HK1232211A1 (zh) | 二甲基吡啶胺衍生物及其醫藥用途 | |
| SG11201609948YA (en) | Lobaplatin crystal, preparation method and pharmaceutical application | |
| IL250913A0 (en) | Platinum (iv) complexes, preparations containing them and their uses | |
| EP3217965C0 (en) | PHARMACEUTICAL PROCESS | |
| PL3386988T3 (pl) | Nowe pochodne dihydropiranopirymidynonu i ich zastosowanie | |
| PL3166945T3 (pl) | Nowe pochodne triazolopirymidynonu lub triazolopirydynonu i ich zastosowanie | |
| LT3127544T (lt) | Priešnavikinis vaistas, kurio sudėtyje yra priešnavikinis platinos kompleksas ir priešnavikinio poveikio stipriklis | |
| ZA201607067B (en) | Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer | |
| ZA201703078B (en) | Pharmaceutical composition comprising bisoprolol and perindoril |